Announcements Trials

Browse Landscape

Phase

Phase 3 3 Phase 2 1

Status

Recruiting 3 Completed 3 Unknown 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1 Endocrine 1

Conditions

Differentiated Thyroid Cancer 1

Interventions

Cisplatin 270 Oxaliplatin 195 Carboplatin 191 Capecitabine 184 Docetaxel 178 apatinib 164 Paclitaxel 163 Bevacizumab 159 Gemcitabine 156 Radiotherapy 147 camrelizumab 146 Fluorouracil 144 Cyclophosphamide 126 Irinotecan 120 Drug Therapy 119 sintilimab 108 Etoposide 99 anlotinib 90 S 1 (combination) 89 Leucovorin 86 pembrolizumab 85 toripalimab 78 Pemetrexed 78 Doxorubicin 77 tislelizumab 76 Dexamethasone 71 Trastuzumab 65 Neoadjuvant Therapy 65 Rituximab 62 Cetuximab 62

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Unknown × Thyrotropin Alfa × Clear all

NCT04447183 2023-10-23

DTC

Suzhou Zelgen Biopharmaceuticals Co.,Ltd

Phase 2 Unknown

EndocrineHead & Neck

Differentiated Thyroid Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡